Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fibroblast growth factor-2
- Development stage
- Unknown
- Lead developer
- D. Bradley Welling
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
FGF-2 (Fibroblast Growth Factor-2), also known as basic FGF, is a recombinant human protein investigated for the treatment of chronic tympanic membrane perforations. In clinical trials led by D. Bradley Welling, MD, PhD, at Harvard Medical School and Massachusetts Eye and Ear, the treatment was administered topically by saturating a gelatin sponge with FGF-2 and placing it into the perforation, followed by the application of Tisseel fibrin glue. FGF-2 functions as a potent mitogen that binds to fibroblast growth factor receptors (FGFRs), triggering cellular proliferation, migration, and neovascularization to promote wound healing and closure of the ear drum. A Phase II randomized, placebo-controlled trial funded by the Department of Defense evaluated its safety and efficacy, though it did not reach statistical significance for the primary endpoint of perforation closure.
- Other names
- FGF-2FGF2FGF 2basic fibroblast growth factorbFGFrecombinant human fibroblast growth factor-2
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)FGFR3 (Fibroblast growth factor receptor 3)αVβ3 (Integrin αVβ3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on fibroblast growth factor-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fibroblast growth factor-2.